前沿速览019期| CAR-T治B淋 前沿览新知
01
CD20双特异性抗体可改善CD19 CAR-T治疗淋巴瘤和慢性淋巴细胞白血病（CLL）的应答：淋巴瘤细胞研究和CLL动物研究
CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models
第一作者：Brinkmann BJ
Blood (IF=20.3). 2024 May 28:blood.2023022682.
全文网址：https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2023022682/516240/CD20-bispecific-antibodies-improve-response-to?redirectedFrom=fulltext
02
CAR-T细胞治疗继发性中枢神经系统淋巴瘤：一项多中心分析
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis
第一作者：Alsouqi A
Am J Hematol (IF=12.8). 2024 May 20.
全文网址：https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27354
03
循环抗CD19 CAR-T细胞及其群体的动力学对DLBCL患者预后的影响
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients
第一作者：Martín-Martín L
Blood Cancer J (IF=12.8). 2024 May 17;14(1):83.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101460/
04
造血细胞移植或CAR-T细胞治疗后第一年接种 SARS-CoV-2疫苗：一项前瞻性多中心观察性研究
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study
第一作者：Hill JA
Clin Infect Dis (IF=11.8). 2024 May 27:ciae291.
全文网址：https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciae291/7683259?redirectedFrom=fulltext&login=false
05
商业化Relma-cel治疗复发/难治性中枢神经系统淋巴瘤的真实世界经验：一项对中国患者的多中心回顾性分析
Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China
第一作者：Yu W
J Immunother Cancer (IF=10.9). 2024 May 27;12(5):e008553.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/38802271/
06
CAR-T细胞疗法并发症的管理：一项欧洲血液和骨髓移植学会的报告
Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation
第一作者：Penack O
Haematologica (IF=10.1). 2024 May 30.
全文网址：https://haematologica.org/article/view/haematol.2023.284810
07
CAR-T细胞疗法后的缓解：淋巴瘤患者能否恢复正常生活？
Remission after CAR T-cell therapy: Do lymphoma patients recover a normal life?
第一作者：Perthus A
Hemasphere (IF=9.1). 2024 May 27;8(5):e72.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/38803454/
08
CAR-T细胞治疗大B细胞淋巴瘤进展后的治疗结局
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
第一作者：Iacoboni G
Hemasphere (IF=9.1). 2024 May 21;8(5):e62.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/38774657/
09
Axicabtagene ciloleucel二线治疗早期复发或原发难治大B细胞淋巴瘤的真实世界经验
Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma
第一作者：Othman T
Br J Haematol (IF=6.5). 2024 May 26.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.19521
10
CAR-T治疗继发性中枢神经系统淋巴瘤患者的结局：一项CIBMTR分析
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis
第一作者：Epperla N
Br J Haematol (IF=6.5). 2024 May 26.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.19569
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.6-3 valid until 2026.6
供稿与审核：临床开发与医学部